Molsidomine 2mg / 4mg Tablets

Each tablet Contains
Molsidomine BP ..................... 2mg
Excipients .......................... Q.S

Each tablet Contains
Molsidomine BP ..................... 4mg
Excipients .......................... Q.S

Each Tablet contains:
Molsidomin ....................... 2/4mg

COMPOSITION:
Molsidomine - 2
Each enteric-coated tablet contains
Molsidomine ....................... 2mg

Molsidomine - 4
Each enteric-coated tablet contains
Molsidomine ....................... 4mg

Molsidomine, an effective long-acting anti-anginal drug:
Molsidomine is an orally active, long acting, NO releasing vasodilator which requires hepatic metabolism for activity but which does not cause pharmacological tolerance. Molsidomine is a NO-releasing prodrug. Liver esterases convert molsidomine to the active metabolite, SIN-1 (half-life in plasma is 1-2 hours), which then releases NO.

Used: in severe cases of angina pectoris.

OVERDOSE:
If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include difficulty breathing, fast heartbeat, tremors, vomiting, restlessness, weakness, fatigue, or dizziness.

Abstract:
Molsidomine was compared with propranolol for anti-anginal efficacy in a double-blind, cross-over, fixed-dose clinical trial, involving 39 patients with moderate, stable angina pectoris, and objective evidence of coronary sclerosis. The incidence of anginal attacks under molsidomine did not differ statistically from that under propranolol. However, propranolol was more effective in reducing the nitroglycerin requirement at the doses used. Ergometry showed that both drugs increased exercise tolerance to a comparable extent. However the rate pressure product during exertion indicates that these drugs achieve this result via different paths, molsidomine having a nitrate-like effect. Unwanted effects during the four week treatment periods were minor and generally tolerable.

Molsidomine is an effective long-acting anti-anginal agent with nitrate-like effects and should be a useful addition to the drugs already in use.

Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. © Copyright 2012. Taj Pharma Group (India). All rights reserved.
Molsidomine 2mg / 4mg Tablets

Pharmaceutical active ingredients:
Molsidomine

Forms:
Tablet; Oral: Molsidomine 2 mg
Tablet; Oral: Molsidomine 4 mg
Injectable; Injection: Molsidomine 2 mg / ml

Destination / Category:
Human
Indications and usages:

ATC
ICD-10

DOSAGE AND ADMINISTRATION

Prevention of ischaemic events
The recommended dose is one tablet once daily.

Acute coronary syndrome
Loading dose: Four tablets.
Maintenance: One tablet daily

PACKAGING INFORMATION:
Molsidomine -2: Blister of 10 tablets
Molsidomine -4: Blister of 10 tablets

For Information about Generic Medicines: genericmedicines@tajpharma.com

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).

Note: We are committed to helping you find the right answers to your questions and concerns. However, this Report is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active Pharmaceutical Ingredients manufacturer, exporter, drug ingredients, pharmaceuticals, India

Additionally, contact information on this Report cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country’s regulations. Please choose one of the given options to contact us and we will respond to

© Copyright 2012  Taj Pharma Group (India), All rights reserved.
This document includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “expected”, “plan”, “goal” believe”, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company’s control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as “relevant persons”). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of the world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai Pharmax and ChemiX association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.

Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.

© Copyright 2011 Taj Pharma Group (India). All rights reserved.